
Sign up to save your podcasts
Or
On this week’s episode of the pod, we discuss postpartum depression disorder (PDD) with guest Dr. Craig Chepke, a board-certified psychiatrist. We kick things off with some statistics and demographics of those who are impacted by PPD. We explore the symptoms, diagnosis, and risk factors of PPD —and distinguish it from the less serious “baby blues”. Throughout the episode, we emphasize the importance of seeking help and breaking the stigma associated with mental health treatment and support. The conversation also covers the development of FDA-approved medications for postpartum depression, including an oral medication called Zurzuvae (zuranolone). We discuss the FDA approval process for Zurzuvae, and the lack of approval for major depressive disorder (MDD) which limits its accessibility and coverage by insurance, making it out of reach for many individuals. We chat about the efficacy and safety of this new medication, highlighting the potential benefits it could offer to individuals in a mental health crisis. The conversation emphasizes the importance of reducing stigma and barriers to treatment, as well as the need for faster-acting medications for depression. We share some personal experiences with mental health issues and treatments. We wrap with a conversation on the impact of FDA approvals on suicide prevention and the future direction of Zurzuvae’s approval (to possibly include other disorders such as MDD), and share some resources available for mental health support. You do not want to miss this episode!
Interested in advertising with us? Please reach out to [email protected], with “Unbiased Science” in the subject line.
PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional.
Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Learn more about your ad choices. Visit megaphone.fm/adchoices
4.4
593593 ratings
On this week’s episode of the pod, we discuss postpartum depression disorder (PDD) with guest Dr. Craig Chepke, a board-certified psychiatrist. We kick things off with some statistics and demographics of those who are impacted by PPD. We explore the symptoms, diagnosis, and risk factors of PPD —and distinguish it from the less serious “baby blues”. Throughout the episode, we emphasize the importance of seeking help and breaking the stigma associated with mental health treatment and support. The conversation also covers the development of FDA-approved medications for postpartum depression, including an oral medication called Zurzuvae (zuranolone). We discuss the FDA approval process for Zurzuvae, and the lack of approval for major depressive disorder (MDD) which limits its accessibility and coverage by insurance, making it out of reach for many individuals. We chat about the efficacy and safety of this new medication, highlighting the potential benefits it could offer to individuals in a mental health crisis. The conversation emphasizes the importance of reducing stigma and barriers to treatment, as well as the need for faster-acting medications for depression. We share some personal experiences with mental health issues and treatments. We wrap with a conversation on the impact of FDA approvals on suicide prevention and the future direction of Zurzuvae’s approval (to possibly include other disorders such as MDD), and share some resources available for mental health support. You do not want to miss this episode!
Interested in advertising with us? Please reach out to [email protected], with “Unbiased Science” in the subject line.
PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional.
Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers.
Learn more about your ad choices. Visit megaphone.fm/adchoices
Learn more about your ad choices. Visit megaphone.fm/adchoices
2,045 Listeners
3,066 Listeners
43,406 Listeners
11,710 Listeners
942 Listeners
495 Listeners
23,310 Listeners
4,460 Listeners
1,435 Listeners
618 Listeners
1,933 Listeners
92 Listeners
412 Listeners
367 Listeners
213 Listeners